Technical Analysis for EYES - Second Sight Medical Products, Inc.

Grade Last Price % Change Price Change
grade C 0.925 -3.64% -0.03
EYES closed down 3.64 percent on Thursday, September 19, 2019, on 1.33 times normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical EYES trend table...

Date Alert Name Type % Chg
Jack-in-the-Box Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Upper Bollinger Band Touch Strength 0.00%
Stochastic Sell Signal Bearish -3.64%
Expansion Breakout Bullish Swing Setup -3.64%
Pocket Pivot Bullish Swing Setup -3.64%
Volume Surge Other -3.64%

Older signals for EYES ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Second Sight Medical Products, Inc. was founded in 1998 with a mission to restore vision to the blind. Today, Second Sight’s Argus II retinal prosthesis provides functional vision to patients blinded by outer retinal degenerations such as retinitis pigmentosa. The company’s innovative technology is the only retinal prosthesis approved by the United States FDA and the first device to receive a CE mark in Europe. The company’s transformative prosthetic device allows blind individuals to gain greater independence in their daily lives. Second Sight believes that its award winning technology will serve as a platform to treat nearly all forms of blindness and could be extended to other neurostimulation applications beyond vision restoration. The Argus II system is currently available in the US and Europe and the company is actively pursuing additional geographic markets. With next generation products under development, the company plans to continue developing, manufacturing and marketing its innovative visual prostethics around the world. Second Sight’s US Headquarters are in Sylmar, California. European Headquarters are in Lausanne, Switzerland.
Medicine Biotechnology Emerging Technologies Medical Devices FDA Vision Blindness Retinitis Pigmentosa Biomedical Engineering Neuroprosthetics Neurostimulation
Is EYES a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.98
52 Week Low 0.635
Average Volume 182,352
200-Day Moving Average 0.836
50-Day Moving Average 0.824
20-Day Moving Average 0.8203
10-Day Moving Average 0.8715
Average True Range 0.0626
ADX 23.55
+DI 36.7862
-DI 9.9246
Chandelier Exit (Long, 3 ATRs ) 0.9322
Chandelier Exit (Short, 3 ATRs ) 0.8578
Upper Bollinger Band 0.9437
Lower Bollinger Band 0.6969
Percent B (%b) 0.92
BandWidth 30.086554
MACD Line 0.0295
MACD Signal Line 0.0151
MACD Histogram 0.0144
Fundamentals Value
Market Cap 52.53 Million
Num Shares 56.8 Million
EPS -0.71
Price-to-Earnings (P/E) Ratio -1.30
Price-to-Sales 12.04
Price-to-Book 3.29
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.02
Resistance 3 (R3) 1.02 0.99 1.00
Resistance 2 (R2) 0.99 0.97 0.99 1.00
Resistance 1 (R1) 0.96 0.95 0.94 0.96 0.99
Pivot Point 0.93 0.93 0.92 0.93 0.93
Support 1 (S1) 0.90 0.90 0.88 0.89 0.86
Support 2 (S2) 0.87 0.89 0.87 0.85
Support 3 (S3) 0.84 0.87 0.85
Support 4 (S4) 0.83